The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.
The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.
复制标题
DOI：
10.1016/j.oraloncology.2016.08.001
复制
发表时间：
2016-10
期刊：
影响因子：
4.8
通讯作者：
Strome SE
中科院分区：
文献类型：
--
作者：
Pai SI;Zandberg DP;Strome SE
我们回顾了目前在头颈部鳞状细胞癌患者中研究的最有前途的免疫检查点途径之一，程序性细胞死亡-1（PD-1）及其配体（PD-L1和PD-L2）的临床知识。我们回顾了正在进行的临床试验和观察到的靶向受体PD-1及其配体PD-L1的相关临床反应。最近的一项III期临床试验（Checkmate 141）表明，与复发性和/或转移性疾病的标准治疗相比，接受抗PD-1单药治疗的头颈癌患者的总生存期有所改善，这就提出了如何最好地将免疫治疗纳入标准治疗的问题。我们讨论了这类新药的反应生物标志物，这是一个积极的调查领域。最后，我们预测了该领域的未来方向，其中了解各种单克隆抗体的Fc部分如何影响其临床疗效，并讨论了我们下一步进展可能发生的领域，例如组合策略。
We review the current clinical knowledge surrounding one of the most promising immune checkpoint pathways currently investigated in head and neck squamous cell carcinoma patients, programmed cell death-1 (PD-1) and its ligands (PD-L1 and PD-L2). We review ongoing clinical trials and associated clinical responses observed with targeting the receptor, PD-1, and its ligand, PD-L1. A recent phase III clinical trial (Checkmate 141) demonstrated an improved overall survival in head and neck cancer patients treated with anti-PD-1 monotherapy as compared to standard of care for recurrent and/or metastatic disease, which raises questions on how best to incorporate immunotherapy in the context of standard of care. We discuss biomarkers of response to this class of novel drugs, which is an area of active investigation. Lastly, we project future directions in the field wherein understanding how the Fc portions of the various monoclonal antibodies may impact their clinical efficacy as well as discuss areas where our next advances may take place, such as combination strategies.
登录
查看更多内容
影响因子：
56.9
作者：
HATHCOCK, KS;LASZLO, G;HODES, RJ
通讯作者：
HODES, RJ
影响因子：
56.9
作者：
FREEMAN, GJ;GRIBBEN, JG;NADLER, LM
通讯作者：
NADLER, LM
影响因子：
16.6
作者：
Johnson DB;Estrada MV;Salgado R;Sanchez V;Doxie DB;Opalenik SR;Vilgelm AE;Feld E;Johnson AS;Greenplate AR;Sanders ME;Lovly CM;Frederick DT;Kelley MC;Richmond A;Irish JM;Shyr Y;Sullivan RJ;Puzanov I;Sosman JA;Balko JM
通讯作者：
Balko JM
影响因子：
32.4
作者：
Butte, Manish J.;Keir, Mary E.;Freeman, Gordon J.
通讯作者：
Freeman, Gordon J.
影响因子：
64.8
作者：
Day, Cheryl L.;Kaufmann, Daniel E.;Walker, Bruce D.
通讯作者：
Walker, Bruce D.